Pharmacokinetic Disposition of Quinolones in Human Body Fluids and Tissues
- 1 January 1989
- journal article
- review article
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 16 (1), 5-24
- https://doi.org/10.2165/00003088-198900161-00004
Abstract
The unique pharmacokinetic properties as well as the body fluid and tissue penetration of quinolones are discussed. Quinolones are well absorbed from the gastrointestinal tract and are eliminated with considerable differences in their terminal half-lives. The major elimination pathways of quinolones are renal excretion and hepatic metabolism. Renally, these drugs undergo the potential excretion mechanisms (glomerular filtration, tubular secretion, reabsorption). In the liver, they are metabolised primarily by oxidation as well as by conjugative pathways. However, the metabolic pattern and extent of metabolism differ significantly between individual agents. Alterations in the pharmacokinetic disposition of these agents in liver and renal failure as well as in elderly patients are observed as predicted from their excretion pattern. In addition, quinolones can interact with a number of other compounds at hepatic (e.g. with xanthine derivatives), renal (with probenecid) and gastrointestinal (with antacids) sites. The volume of distribution of quinolones is considerably higher than body volume, which suggests intracellular penetration. Studies on tissue penetration show that concentrations exceeding plasma levels are obtained in most tissues. The highest tissue/plasma concentration ratios are achieved in lung and kidney, whereas concentrations in fat are considerably lower than in plasma. Body fluid penetration is introduced as a new approach to evaluate distribution kinetics of quinolones. With the exception of those in nasal secretions and ejaculate, body fluid levels of these drugs rarely reach plasma levels. The body fluid penetration model allows for differentiation among individual agents. There is no apparent relationship between differences in body fluid penetration of quinolones and differences in volume of distribution. For the clinical use of these drugs it is important that the concentrations achieved in body fluids and tissues are sufficient to kill most pathogens. A discussion on the relationship between plasma and tissue levels and the MICs of quinolones is, however, beyond the scope of this article.Keywords
This publication has 42 references indexed in Scilit:
- Pharmacokinetics and body fluid penetration of fleroxacin in healthy volunteersJournal of Antimicrobial Chemotherapy, 1988
- Penetration of enoxacin into bronchial secretionsAntimicrobial Agents and Chemotherapy, 1987
- The comparative pharmacokinetics of five quinolonesJournal of Antimicrobial Chemotherapy, 1986
- Diffusion of ofloxacin into the cerebrospinal fluid in patients with bacterial meningitisInfection, 1986
- Penetration of ciprofloxacin into kidney, fat, muscle and skin tissueEuropean Journal of Clinical Microbiology & Infectious Diseases, 1986
- Further methodological improvement in antibiotic bone concentration measurements: penetration of ofloxacin into bone and cartilage.1986
- The Clinical Relevance of Protein Binding and Tissue Concentrations in Antimicrobial TherapyClinical Pharmacokinetics, 1986
- Norfloxacin penetration into human renal and prostatic tissuesAntimicrobial Agents and Chemotherapy, 1985
- Single- and multiple-dose pharmacokinetics of pipemidic acid in normal human volunteersAntimicrobial Agents and Chemotherapy, 1984
- The Influence of Protein Binding upon Tissue Fluid Levels of Six -Lactam AntibioticsThe Journal of Infectious Diseases, 1980